Mehalick David 4

What Happened
David Mehalick, reported as a 10% owner of Coeptis Therapeutics Holdings, Inc. (COEP), acquired shares via two transactions on Feb 11, 2026. He exercised stock options (transaction code M) to acquire 148,875 shares at a weighted-average exercise price of $7.05, for total consideration of $1,049,569. He also received a grant of 51,250 restricted shares (transaction code A) issued at $0.00 in connection with an option exchange program.

Key Details

• Transaction date: February 11, 2026; Form 4 filed February 13, 2026.
• Option exercise: 148,875 shares acquired at $7.05 each (F1) — total paid ≈ $1,049,569.
• Restricted stock grant: 51,250 shares issued at $0.00 (F2) as part of an option-exchange program where underwater options were surrendered.
• Transaction codes: M = exercise/conversion of derivative; A = grant/award.
• Shares owned after the transaction: not specified in the information provided.
• Filing timeliness: Form 4 was filed two days after the transaction date; no indication in the filing that it was late.

Context

• The option exercise is an acquisition (insider paid cash to convert options into shares) and not a sale — often viewed as more informative than routine sales but does not, by itself, indicate motive.
• The restricted stock grant (F2) resulted from surrendering underwater options under an exchange program, a common corporate practice to address option value misalignment.
• As a 10% owner, Mehalick is a significant shareholder rather than necessarily a company executive; holdings and exercises by such insiders can reflect capital commitment but should be reviewed alongside other filings and company developments.